Nurix Therapeutics, Inc.
NRIX
$10.55
$0.313.03%
NASDAQ
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Net Income | -56.35M | -58.55M | -48.96M | -44.55M | -41.52M |
| Total Depreciation and Amortization | 4.13M | 3.00M | 4.15M | 4.09M | 3.89M |
| Total Amortization of Deferred Charges | -- | 1.30M | -- | -- | -- |
| Total Other Non-Cash Items | 5.17M | 5.05M | 5.33M | 6.69M | 5.89M |
| Change in Net Operating Assets | -14.03M | 449.00K | -2.70M | -5.94M | -10.21M |
| Cash from Operations | -61.09M | -48.75M | -42.18M | -39.71M | -41.95M |
| Capital Expenditure | -3.49M | -2.11M | -2.35M | -1.94M | -2.88M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 29.02M | -138.71M | -18.99M | -129.13M | 38.40M |
| Cash from Investing | 25.53M | -140.82M | -21.34M | -131.07M | 35.51M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.47M | 200.52M | 45.77M | 237.77M | 1.62M |
| Repurchase of Common Stock | -- | -15.00K | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 15.00K | 0.00 | -15.00K | -- |
| Cash from Financing | 1.47M | 200.52M | 45.77M | 237.75M | 1.62M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -34.08M | 10.95M | -17.75M | 66.98M | -4.81M |